Peter Frederick, MD, FACOG
Areas of Expertise:
Complicated Gynecologic Surgery
Robotic and Minimally Invasive Approaches to Gynecologic Surgery
I have been on the faculty at Roswell Park in the Department of Gynecologic Oncology since 2010. Originally from Buffalo, NY, I did my medical school and residency training in Obstetrics/Gynecology at the University at Buffalo School of Medicine and Biomedical Sciences. This was followed by three years of advanced fellowship training in gynecologic oncology at the University of Alabama at Birmingham, focusing on all aspects of gynecologic cancer care, including advanced and minimally invasive surgical techniques, chemotherapy, gynecologic cancer screening and surveillance, as well as basic science research focusing on cell death in ovarian cancer.
My areas of clinical interest include all cancers of the female reproductive system, including uterine, ovarian, cervical, vulvar, and vaginal cancer. As the Director of Minimally Invasive Surgery for the Department of Gynecologic Oncology, I have taken a leading role in developing and promoting the robotics program at Roswell Park. I have performed hundreds of robotic surgeries to treat and stage gynecologic cancers, as well as complex benign conditions such as endometriosis. I have lectured regionally and nationally on robotic surgery and the ground-breaking benefits it provides for well-selected patients. I have also trained and proctored dozens of surgeons in robotic surgical techniques.
I am a Fellow of the American Congress of Obstetricians and Gynecologists, as well as an active member in numerous professional organizations, including the Gynecologic Oncology Group, the Society of Gynecologic Oncology, the Buffalo Gynecologic and Obstetric Society, and the American Society of Clinical Oncology. I am board certified in Obstetrics and Gynecology and Gynecologic Oncology and have co-authored over 40 publications, book chapters, and abstracts.
Strategies for the prevention and treatment of ovarian cancer
Novel immunological therapies for endometrial cancer
Clinical trials in gynecologic oncology
Education and Training:
MD - State University of New York at Buffalo, Buffalo, NY
BA - University of Rochester, Rochester, NY
State University of New York at Buffalo, Buffalo, NY (Gynecology/Obstetrics)
University of Alabama at Birmingham, Birmingham, AL (Gynecologic Oncology)
- The clinical impact of computed tomography immediately following primary chemotherapy in patients with epithelial ovarian cancer. Clinical ovarian cancer 2010; 3(1):52-55 .
- Robotic surgery in gynecologic oncology fellowship programs in the USA: a survey of fellows and fellowship directors. International journal of medical robotics and computer assisted surgery 2010; 6(4):405-412 .
- Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer research 2009; 69(13):5498-5504 .
- Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma. PloS one 2011; 6(3):e18066 .
- Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies. International journal of gynecological cancer 2010; 20(8):1321-1325 .
- Young patients with endometrial carcinoma selected for conservative treatment: a need for vigilance for synchronous ovarian carcinomas, case report and literature review. Gynecologic oncology 2007; 104(3):757-760 .
- Assessment of risk factors for 30-day hospital readmission after surgical cytoreduction in epithelial ovarian carcinoma. International journal of gynecological cancer 2011; 21(5):806-810 .
- Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. Gynecologic oncology 2011; 122(3):532-535 .
- Tryptophan degradation by indoleamine 2,3-dioxygenase promotes preferential accumulation of CD4(+)CD25(high)FOXP3(+) regulatory T cells in human ovarian cancer. Gynecologic oncology 2008; 108(3 Suppl. 1):338 .
- Aldolase mRNA expression in endometrial cancer and the role of clotrimazole in endometrial cancer cell viability and morphology. Histopathology 2011; 59(5):1015-1018 .
- Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer. International journal of gynecological cancer 2011; 21(5):831-836 .
- Double prophylaxis for deep venous thrombosis in patients with gynecologic oncology who are undergoing laparotomy does preoperative anticoagulation matter? . International journal of gynecological cancer 2011; 21(6):1131-1134 .
- Claudin7 and moesin in endometrial Adenocarcinoma; a retrospective study of 265 patients. BMC research notes 2012; 5 :65 .
- Chemoresistance in patients with papillary serous carcinoma of the ovary. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #1714 .
- Adjuvant treatment for uterine leiomyosarcoma. Gynecologic oncology 2012; 125(Suppl. 1):S159 .
- Photodynamic therapy effectively palliates gynecologic malignancies. Gynecologic oncology 2012; 125(Suppl. 1):S81 .
- Identification of a subset of stage IV ovarian carinomas with improved overall survival. Gynecologic oncology 2012; 125(Suppl. 1):S102 .